FDA’s quest to regulate CBD

Through years of inertia, U.S. regulators have allowed the CBD market to become the “Wild West” when they could—and according to many hemp business executives and industry lawyers, should—have intervened long ago.

Josh Long, Associate editorial director, SupplySide Supplement Journal

February 19, 2020

2 Min Read
FDA’s quest to regulate CBD.jpg

It’s the year 2024—and Elizabeth Warren is deep into her first term as president of the United States.

Student loans have been forgiven, automobiles are banned in national parks, the Kardashians are on an intergalactic vacation broadcast live via Instagram, and Congress has legalized recreational marijuana.

Buried on the inside pages of The Washington Post, The New York Times and Wall Street Journal: FDA has drafted a rule that, once finalized, will formally authorize the marketing of CBD in dietary supplements. The 2024 rule—a decade late and dollar short—is parodied on “Saturday Night Live” as “stoned” bureaucrats at FDA headquarters taste pot brownies on a 500-page “draft” packet and watch an episode of “The Flintstones” in which Fred fakes an illness.

The French philosopher Voltaire reportedly said, “The best is the enemy of the good.” FDA does not have the luxury of an eternity pondering the “best” or “perfect” rulemaking to police and regulate hemp-based CBD supplements.

Through years of inertia, U.S. regulators have allowed the CBD market to become the “Wild West” when they could—and according to many hemp business executives and industry lawyers, should—have intervened long ago to either actively regulate manufacturers and/or enforce vigorously against companies openly flouting the law.

FDA should establish dosage limits in an expedited rulemaking, but not for the express purpose of solving its growing safety concerns. The agency could, for example, address the “incentives” challenge to invest in costly drugs by setting a maximum level of CBD in supplements markedly lower than the dose in Epidiolex—the CBD medicine GW Pharmaceuticals markets for children with severe forms of epilepsy.

The regulation also would need to preserve the incentives of supplement manufacturers to go to market with an effective dose to promote health and wellness, including yet-to-be-proven structure/function claims for hemp extracts like “occasional sleeplessness.” In other words, the maximum dose allowed in a supplement couldn’t be so low as to eliminate the purported health benefits of non-FDA-approved CBD.

I’m not suggesting FDA would have an easy task or that its regulation would pacify all the stakeholders.

But FDA’s rule need not contain hundreds of pages of new safety requirements for CBD-containing supplements. Instead, the agency should demand compliance with a comprehensive law already on the books: the Federal Food, Drug and Cosmetic Act (FD&C), which has been amended over the years, including through DSHEA.

To read this article in its entirety, check out the “Hemp/CBD: Market evolution” digital magazine.

About the Author

Josh Long

Associate editorial director, SupplySide Supplement Journal , Informa Markets Health and Nutrition

Josh Long directs the online news, feature and op-ed coverage at SupplySide Supplement Journal (formerly known as Natural Products Insider), which targets the health and wellness industry. He has been reporting on developments in the dietary supplement industry for over a decade, with a focus on regulatory issues, including at the Food and Drug Administration.

He has moderated and/or presented at industry trade shows, including SupplySide East, SupplySide West, Natural Products Expo West, NBJ Summit and the annual Dietary Supplement Regulatory Summit.

Connect with Josh on LinkedIn and ping him with story ideas at [email protected]

Education and previous experience

Josh majored in journalism and graduated from Arizona State University the same year "Jake the Snake" Plummer led the Sun Devils to the Rose Bowl against the Ohio State Buckeyes. He also holds a J.D. from the University of Wyoming College of Law, was admitted in 2008 to practice law in the state of Colorado and spent a year clerking for a state district court judge.

Over more than a quarter century, he’s written on various topics for newspapers and business-to-business publications – from the Yavapai in Arizona and a controversial plan for a nuclear-waste incinerator in Idaho to nuanced issues, including FDA enforcement of the Dietary Supplement Health and Education Act of 1994 (DSHEA).

Since the late 1990s, his articles have been published in a variety of media, including but not limited to, the Cape Cod Times (in Massachusetts), Sedona Red Rock News (in Arizona), Denver Post (in Colorado), Casper Star-Tribune (in Wyoming), now-defunct Jackson Hole Guide (in Wyoming), Colorado Lawyer (published by the Colorado Bar Association) and Nutrition Business Journal.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like